Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European Inspections Present New Challenges to U.S. Manufacturers

This article was originally published in The Gold Sheet

Executive Summary

DANGEROUS CONVERSATIONS are at the heart of a European inspections process that fundamentally differs from FDA’s approach. There is little guidance about the process, which is geared toward reaching conclusions rather than building a case. The European Union inspectors are more experienced, less by-the-book, more likely to chat with workers on the shop floor, experts say. Their inspections tend to be quicker, and can vary by their country of origin

You may also be interested in...



Emergent Suspends COVID-19 Vaccine API Manufacturing As US FDA Inspects Bayview Plant

After discovery of viral vector cross-contamination, AstraZeneca quit, J&J took control and the FDA launched inspection.

Industry ICH Proposal Would Limit International Regulatory Oversight Of Manufacturing Models

The focus would be on high-impact changes to high-impact models under approach advocated by BioPhorum, IQ Consortium and PPAR.

Remote Site Visits Will Help US FDA Keep Reviews On Track As Pandemic Constraints Continue

Guidance discusses what are generically called virtual inspections, but which the agency terms “remote interactive evaluations.” As site inspections remain constrained by the pandemic, remote interactive evaluations “should help FDA operate within normal timeframes,” the document says.

UsernamePublicRestriction

Register

PS000118

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel